Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Research & Development: 2014-2025

Historic Research & Development for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to $16.6 million.

  • KalVista Pharmaceuticals' Research & Development fell 34.21% to $16.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was $91.0 million, marking a year-over-year increase of 32.86%. This contributed to the annual value of $71.7 million for FY2025, which is 16.78% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported Research & Development of $16.6 million as of Q2 2025, which was down 37.59% from $26.6 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Research & Development registered a high of $26.6 million during Q3 2024, and its lowest value of $16.6 million during Q2 2025.
  • Moreover, its 2-year median value for Research & Development was $23.9 million (2024), whereas its average is $22.7 million.
  • Data for KalVista Pharmaceuticals' Research & Development shows a maximum YoY plummeted of 34.21% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows KalVista Pharmaceuticals' Research & Development stood at $26.6 million in 2024, then crashed by 34.21% to $16.6 million in 2025.
  • Its Research & Development stands at $16.6 million for Q2 2025, versus $26.6 million for Q3 2024 and $25.2 million for Q2 2024.